Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URIC CKD study: febuxostat vs benzbromarone in CKD with hypertension and hyperuricemia
jRCTs071180033Completed
- Sponsor
- Teijin Pharma
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in chronic kidney disease (CKD), hyperuricemia and hypertension (HTN) comparing Febuxostat with Benzbromarone (2 arms). Primary endpoint: Primary: rate of change in estimated GFR from baseline to 52 weeks. Started Oct 2017; status: completed.
02
Drugs
febuxostatbenzbromarone
03
Conditions
chronic kidney disease (CKD)hyperuricemiahypertension (HTN)
Beyond the preview
Go deeper on jRCTs071180033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180033.